Neuroimaging and therapeutics in movement disorders

NeuroRx

Volumn 2, Issue 2, 2005, Pages 361-371

  Eckert, Thomas ^a,b   Eidelberg, David ^b,c  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b N Shore Long Isl Jewish Hlth S ^*  (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dystonia; Huntington's disease; Magnetic resonance imaging (MRI); Movement disorders; Parkinson's disease; Positron emission tomography (PET); Tourette's syndrome

Indexed keywords

6 FLUORODOPA F 18; DIHYDROTETRABENAZINE; DIHYDROTETRABENAZINE C 11; DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE F 18; LEVODOPA; NEUROPROTECTIVE AGENT; PRAMIPEXOLE; UNCLASSIFIED DRUG;

BRAIN PERFUSION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPAMINERGIC SYSTEM; DYSTONIA; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; STEREOTAXIC SURGERY;

EID: 16344381905     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.2.2.361     Document Type: Article

References (124)

1. Brooks DJ. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx 2:226-236, 2005.
2. Ravina B, Eidelberg D, Ahlskog JE, Albin R, Brooks DJ, Carbon M, et al. The role of radiotracer imaging in Parkinson's disease. Neurology 64:208-215, 2005.
3. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14:783-801, 1994.
4. Feigin A, Antonini A, Fukuda M, De Notaris R, Benti R, Pezzoli G, et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 17:1265-1270, 2002.
5. Eckert T, Eidelberg D. The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson's disease and multiple system atrophy. Clin Auton Res 14:84-91, 2004.
6. Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 53:S110-S118, 2003.
7. Marek K, Jennings D, Seibyl J. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann Neurol 53:S160-166, 2003.
8. Parkinson-Study-Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653-1661, 2002.
9. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508, 2004.
10. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93-101, 2003.
11. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Silbersweig D, et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Ann Neurol 39:450-459, 1996.
12. Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain 124:1601-1609, 2001.
13. Su PC, Ma Y, Fukuda M, Mentis MJ, Tseng HM, Yen RF, et al. Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann Neurol 50:514-520, 2001.
14. Trošt M, Su PC, Barnes A, Su SL, Yen RF, Tseng HM, et al. Evolving metabolic changes during the first postoperative year after subthalamotomy. J Neurosurg 99:872-878, 2003.
15. Devous MD Sr. Single-photon emission computed tomography in neurotherapeutics. NeuroRx 2:237-249, 2005.
16. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64:314-319, 1998.
17. Pate BD, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34:331-338, 1993.
18. Snow B, Tooyama I, McGeer E, Yamada T, Calne D, Takahashi H, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34:324-330, 1993.
19. Tissingh G, Bergmans P, Booij J, Winogrodzka A, Stoof JC, Wolters EC, et al. [123I]β-GT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med 24:1171-1174, 1997.
20. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl J Med 39:1521-1530, 1998.
21. Dhawan V, Eidelberg D. SPECT imaging in Parkinson's disease. Adv Neurol 86:205-213, 2001.
22. Fahn S, Elton R, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, eds. Recent developments in Parkinson's disease. New York: MacMillan, pp 153-163, 1987.
23. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic-evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47:493-503, 2000.
24. Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 14:436-442, 1999.
25. Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab 20:1604-1609, 2000.
26. Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 14:940-946, 1999.
27. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 56:1559-1564, 2001.
28. Nakamura T, Dhawan V, Chaly T, Fukuda M, Ma Y, Breeze R, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 50:181-187, 2001.
29. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-414, 2003.
30. Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 52:628-634, 2002.
31. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2:1137-1140, 1999.
32. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719, 2001.
33. Lindvall O. Stem cells for cell therapy in Parkinson's disease. Pharmacol Res 47:279-287, 2003.
34. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 45:1995-2004, 1995.
35. Alexander GE, Moeller JR. Application of the scaled subproflle model to functional imaging in neuropsychiatric disorders: a principal component approach to modeling brain function in disease. Hum Brain Mapp 2:1-16, 1994.
36. Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 40:1264-1269, 1999.
37. Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med 42:1591-1595, 2001.
38. Eidelberg D, Moeller JR, Antonini A, Kazumata K, Nakamura T, Dhawan V, et al. Functional brain networks in DYT1 dystonia. Ann Neurol 44:303-312, 1998.
39. Trošt M, Carbon M, Edwards C, Ma Y, Raymond D, Mentis MJ, et al. Primary dystonia: is abnormal functional brain architecture linked to genotype? Ann Neurol 52:853-856, 2002.
40. Eidelberg D, Moeller JR, Antonini A, Kazumata K, Dhawan V, Budman C, et al. The metabolic anatomy of Tourette's syndrome. Neurology 48:927-934, 1997.
41. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. Assessment of disease severity in parkinsonism with fluorine-18- fluorodeoxyglucose and PET. J Nucl Med 36:378-383, 1995.
42. Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab 16:385-398, 1996.
43. Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 22:236-245, 2004.
44. Moeller JR, Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing. Brain 120:2197-2206, 1997.
45. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 5:203-213, 1990.
46. Eidelberg D, Moeller JR, Kazumata K, Antonini A, Sterio D, Dhawan V, et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 120:1315-1324, 1997.
47. Alsop DC, Casement M, Press D. Increased hippocampal perfusion in early Alzheimer's disease. Proc Intl Soc Mag Reson Med 11:A178, 2003.
48. Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry 159:746-754, 2002.
49. Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM. The subthalamic nucleus in the context of movement disorders. Brain 127:4-20, 2004.
50. Volkmann J Deep brain stimulation for the treatment of Parkinson's disease. J Clin Neurophysiol 21:6-17, 2004.
51. Antonini A, Moeller JR, Nakamura T, Spetsieris P, Dhawan V, Eidelberg D. The metabolic anatomy of tremor in Parkinson's disease. Neurology 51:803-810, 1998.
52. Fukuda M, Barnes A, Simon ES, Holmes A, Dhawan V, Giladi N, et al. Thalamic stimulation for parkinsonian tremor: correlation between regional cerebral blood flow and physiological tremor characteristics. Neuroimage 21:608-615, 2004.
53. Trošt M, Simon ES, Dhawan V, Okulski J, Fodstad H, Eidelberg D. Clinical and metabolic brain changes in tremor predominant Parkinson's disease patients treated with Vim deep brain stimulation. Mov Disord 199:5383, 2004.
54. Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 57:2083-2088, 2001.
55. Brown RG, Dowsey PL, Brown P, Jahanshahi M, Pollak P, Benabid AL, et al. Impact of deep brain stimulation on upper limb akinesia in Parkinson's disease. Ann Neurol 45:473-488, 1999.
56. Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 16:1014-1022, 2001.
57. Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M, et al. Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab 24:7-16, 2004.
58. Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 48:119-125, 1997.
59. Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 54:937-944, 1997.
60. Litvan I, Booth V, Wenning GK, Bartko JJ, Goetz CG, McKee A, et al. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neurol Transm 105:217-227, 1998.
61. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861-870, 2002.
62. Osaki Y, Wenning GK, Daniel SE, Hughes A, Lees AJ, Mathias CJ, et al. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology 59:1486-1491, 2002.
63. Hughes AJ, Daniel SE, Blankson S, Lees A. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50:140-148, 1993.
64. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 22:8-12, 1987.
65. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 38:1031-1034, 1988.
66. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn N. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12:133-147, 1997.
67. Krack P, Pollak P, Limousin P, Hoffmann D, Benazzouz A, Le Bas JF, et al. Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 43:180-192, 1998.
68. Litvan I, Chase TN, eds. Traditional and experimental therapeutic approaches. New York: Oxford University Press, 1992.
69. Wenning GK, Pramstaller PP, Ransmayr G, Poewe W. [A typical Parkinson syndrome.] Nervenarzt 68:102-115, 1997.
70. Tarsy D, Apetauerova D, Ryan P, Norregaard T. Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy. Neurology 61:247-249, 2003.
71. Visser-Vandewalle V, Temel Y, Colle H, van der Linden C. Bilateral high-frequency stimulation of the subthalamic nucleus in patients with multiple system atrophy-parkinsonism. Report of four cases. J Neurosurg 98:882-887, 2003.
72. Lezcano E, Gomez-Esteban JC, Zarranz JJ, Alcaraz R, Atares B, Bilbao G, et al. Parkinson's disease-like presentation of multiple system atrophy with poor response to STN stimulation: a clinicopathological case report. Mov Disord 19:973-977, 2004.
73. Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, et al. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 57:205-208, 2000.
74. Piccini P, de Yebenez J, Lees AJ, Ceravolo R, Turjanski N, Pramstaller P, et al. Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography. Arch Neurol 58:1846-1851, 2001.
75. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 43:1324-1330, 2002.
76. Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, Eidelberg D. Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study. Synapse 45:125-133, 2002.
77. Antonini A, Vontobel P, Psylla M, Gunther I, Maguire PR, Missimer J, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 52:1183-1190, 1995.
78. Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120:2187-2195, 1997.
79. Ghaemi M, Milker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 73:517-523, 2002.
80. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53:1020-1025, 1999.
81. Druschky A, Hilz MJ, Platsch G, Radespiel-Troger M, Druschky K, Kuwert T, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 175:3-12, 2000.
82. Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54:697-702, 2000.
83. Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 60:922-927, 2003.
84. Eckert T, Sailer M, Kaufmann J, Schrader C, Peschel T, Bodammer N, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 21:229-235, 2004.
85. Martin WR, Beckman JH, Calne DB, Adam MJ, Harrop R, Rogers JG, et al. Cerebral glucose metabolism in Parkinson's disease. Can J Neurol Sci 11:169-173, 1984.
86. Wolfson LI, Leenders KL, Brown LL, Jones T. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology 35:1399-1405, 1985.
87. Gilman S, Markel DS, Koeppe RA, Junck L, Kluin KJ, Gebarski SS, et al. Cerebellar and brainstem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography. Ann Neurol 23:223-230, 1988.
88. De Volder AG, Francart J, Laterre C, Dooms G, Bol A, Michel C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 26:239-247, 1989.
89. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 33:518-527, 1993.
90. Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study. J Neurol Sci 144:77-83, 1996.
91. Antonini A, Kazumata K, Feigin A, Mandel F, Dhawan V, Margouleff C, et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 13:268-274, 1998.
92. Taniwaki T, Nakagawa M, Yamada T, Yoshida T, Ohyagi Y, Sasaki M, et al. Cerebral metabolic changes in early multiple system atrophy: a PET study. J Neurol Sci 200:79-84, 2002.
93. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 24:399-406, 1988.
94. Leenders KL, Frackowiak RS, Lees AJ. Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 111:615-630, 1988.
95. Blin J, Baron JC, Dubois B, Pillon B, Cambon H, Cambier J, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 47:747-752, 1990.
96. Blin J, Vidailhet MJ, Pillon B, Dubois B, Feve JR, Agid Y. Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 7:348-354, 1992.
97. Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 54:856-862, 1991.
98. Laureys S, Salmon E, Garraux G, Peigneux P, Lemaire C, Degueldre C, et al. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J Neurol 246:1151-1158, 1999.
99. Eckert T, Barnes A, Frucht S, Dhawan V, Feigin A, Eidelberg D. Differential diagnosis of parkinsonian disorders: the diagnostic value of FDG PET. Mov Disord 19:S376, 2004.
100. Feigin A, Ma Y, Zgaljardic D, Carbon M, Dhawan V, Eidelberg D. PET measures of longitudinal progression in presymptomatic Huntington's disease. Neurology 60(Suppl 1):A246, 2003.
101. Feigin A, Budman C, Zgaljardic D, Dhawan V, Eidelberg D. Metabolic brain networks in Tourette syndrome. Mov Disord 17(Suppl 5):S339, 2002.
102. Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126:1127-1135, 2003.
103. Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63:66-72, 2004.
104. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119:2085-2095, 1996.
105. Klein C, Breakefield XO, Ozelius LJ. Genetics of primary dystonia. Semin Neurol 19:271-280, 1999.
106. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Przedborski S, et al. The metabolic topography of idiopathic torsion dystonia. Brain 118:1473-1484, 1995.
107. Eidelberg D. Brain networks and clinical penetrance: lessons from hyperkinetic movement disorders. Curr Opin Neurol 16:471-474, 2003.
108. Ghilardi MF, Carbon M, Silvestri G, Dhawan V, Tagliati M, Bressman S, et al. Impaired sequence learning in carriers of the DYT1 dystonia mutation. Ann Neurol 54:102-109, 2003.
109. Bressman SB. Dystonia genotypes, phenotypes, and classification. Adv Neurol 94:101-107, 2004.
110. Carbon M, Kingsley PB, Su S, Smith GS, Spetsieris P, Bressman S, et al. Microstructural white matter changes in carriers of the DYT1 gene mutation. Ann Neurol 56:283-286, 2004.
111. Carbon M, Su S, Dhawan V, Raymond D, Bressman S, Eidelberg D. Regional metabolism in primary torsion dystonia: effects of penetrance and genotype. Neurology 62:1384-1390, 2004.
112. Jenkins IH, Fernandez W, Playford ED, Lees AJ, Frackowiak RS, Passingham RE, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 32:749-757, 1992.
113. Feigin A, Ghilardi MF, Fukuda M, Mentis MJ, Dhawan V, Barnes A, et al. Effects of levodopa infusion on motor activation responses in Parkinson's disease. Neurology 59:220-226, 2002.
114. Haslinger B, Erhard P, Kampfe N, Boecker H, Rummeny E, Schwaiger M, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 124:558-570, 2001.
115. Fukuda M, Mentis M, Ghilardi MF, Dhawan V, Antonini A, Hammerstad J, et al. Functional correlates of pallidal stimulation for Parkinson's disease. Ann Neurol 49:155-164, 2001.
116. Ceballos-Baumann AO. Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT. J Neurol 250:115-23, 2003.
117. Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage 23:1-16, 2004.
118. Sadato N, Ibanez V, Deiber MP, Campbell G, Leonardo M, Hallett M. Frequency-dependent changes of regional cerebral blood flow during finger movements. J Cereb Blood Flow Metab 16:23-33, 1996.
119. Dai TH, Liu JZ, Sahgal V, Brown RW, Yue GH. Relationship between muscle output and functional MRI-measured brain activation. Exp Brain Res 140:290-300, 2001.
120. Mentis MJ, Dhawan V, Nakamura T, Ghilardi MF, Feigin A, Edwards C, et al. Enhancement of brain activation during trial-and-error sequence learning in early PD. Neurology 60:612-619, 2003.
121. Fukuda M, Ghilardi MF, Carbon M, Dhawan V, Ma Y, Feigin A, et al. Pallidal stimulation for parkinsonism: improved brain activation during sequence learning. Ann Neurol 52:144-152, 2002.
122. Feigin A, Ghilardi MF, Carbon M, Edwards C, Fukuda M, Dhawan V, et al. Effects of levodopa on motor sequence learning in Parkinson's disease. Neurology 60:1744-1749, 2003.
123. Carbon M, Ghilardi MF, Feigin A, Fukuda M, Silvestri G, Mentis MJ, et al. Learning networks in health and Parkinson's disease: reproducibility and treatment effects. Hum Brain Mapp 19:197-211, 2003.
124. Bammer R, Skare S, Newbould R, Liu C, Thijs V, Ropele S, Clayton DB, Krueger G, Moseley ME, Glover GH. Foundations of advanced magnetic resonance imaging. NeuroRx 2:167-196, 2005.